ClearPoint Neuro Reports First Quarter 2022 Results

SOLANA BEACH, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its first quarter ended March 31, 2022.

First Quarter Highlights

  • Reported record quarterly revenue of $5.0 million, a 25% year-over-year increase;
  • Installed four additional global sites with expected first cases in Q2;
  • Increased biologics and drug delivery revenue to $2.2 million, a 30% year-over-year increase;
  • Achieved additional biologics and drug delivery relationships, bringing current count of active partners to approximately 45 therapeutic partners;
  • Signed an agreement with Philips to enable access to technology to allow for use of the Maestro™ Brain Model in the operating room with Computed Tomography; and
  • Began development of a proprietary patient-facing digital health app for drug delivery and brain-computer interface with Higgs-Boson Health to concentrate patient resources, reduce postponements and track quality of life data before and after treatments.

Business Outlook

  • The Company is increasing the low-end revenue range estimate and now expects full year 2022 revenue between $21.0 and $22.0 million.

“The ClearPoint Neuro Team has continued to execute against our four-pillar growth strategy in the first quarter and celebrated a number of successes along the way to get 2022 off to a great start,” commented Joe Burnett, President and CEO. “First, we achieved record quarterly revenue in both Functional Neurosurgery Navigation and Biologics and Drug Delivery, yielded total revenue of $5.0 million which represents first quarter year-over-year growth of 25%. These results were achieved in spite of Omicron related surgery cancellations and postponements, particularly throughout January and early February in the United States and Europe. Our Biologics and Drug Delivery team added additional partners, bringing our current total to approximately 45. The Functional Neurosurgery Navigation team successfully tested pre-clinical prototypes for Micro-Electric Recording and Brain Computer Interface navigation systems in collaboration with BlackRock Neurotech, and submitted ClearPoint Array 1.1 software to the FDA which has subsequently been approved here in the second quarter. Our Therapy Team continues to work with the FDA and Clinical Trial sites in the EU to advance the ClearPoint Neuro-exclusive laser platform and we continue to expect first human cases in the second half of 2022. Our strong first quarter gives our team confidence to increase our range of expected revenue for 2022 to between $21.0 and $22.0 million which would represent between 30 – 35% growth year-over-year.”

Financial Results – Quarter Ended March 31, 2022

Total revenue was $5.0 million for the three months ended March 31, 2022, and $4.0 million for the three months ended March 31, 2021, which represents an increase of $1.0 million, or 25%.

Functional neurosurgery navigation and therapy revenue, increased 17% to $2.2 million for the three months ended March 31, 2022, from $1.9 million for the same period in 2021. The growth was driven by higher service revenue.

Biologics and drug delivery revenue, which includes sales of disposable products and services related to customer-sponsored clinical trials utilizing our products, increased 30% to $2.2 million for the three months ended March 31, 2022, from $1.7 million for the same period in 2021. This increase was fueled by growth in service revenue.

Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software, and of related services, increased 41% to $0.6 million for the three months ended March 31, 2022, from $0.5 million for the same period in 2021.

Gross margin for the three months ended March 31, 2022, was 65%, in line with the same period in 2021.

Operating expenses for the first quarter of 2022 were $7.1 million, compared to $4.8 million for the first quarter of 2022. The increase was mainly driven by the increase in headcount and product development expenses.

At March 31, 2022, the Company had cash and cash equivalents totaling $49.7 million as compared to $54.1 million at December 31, 2021, with the decrease resulting primarily from the use of cash in operating activities.

Teleconference Information

Investors and analysts are invited to listen to a live broadcast review of the Company's 2022 first quarter on Wednesday, May 11, 2022 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here: Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until June 10, 2022, by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's website at, on the “Investor Relations” page.

About ClearPoint Neuro

ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active sites in the United States, Canada, and Europe. ClearPoint Neuro is partnered with approximately 45 biologics/pharmaceutical companies and academic centers, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 5,000 cases have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit

Forward-Looking Statements

Statements in this press release and in the teleconference referenced above concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of the COVID-19 pandemic and the measures adopted to contain its spread; future revenue from sales of the Company’s ClearPoint Neuro Navigation System products; the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products; and risks inherent in the research and development of new products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, which has been filed with the Securities and Exchange Commission, and the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2022, which the Company intends to file with the Securities and Exchange Commission on or before May 16, 2022.

Consolidated Statements of Operations
(Dollars in thousands, except for per share data)

  For The Three Months Ended
March 31,
    2022       2021  
Product revenue $ 3,163     $ 3,162  
Service and other revenue   1,868       868  
Total revenue   5,031       4,030  
Cost of revenue   1,785       1,416  
Gross profit   3,246       2,614  
Research and development costs   2,533       1,563  
Sales and marketing expenses   1,845       1,575  
General and administrative expenses   2,732       1,657  
Operating loss   (3,864 )     (2,181 )
Other expense:      
Other income (expense), net   11       (25 )
Interest expense, net   (106 )     (332 )
Net loss $ (3,959 )   $ (2,538 )
Net loss per share attributable to common stockholders:      
Basic and diluted $ (0.17 )   $ (0.13 )
Weighted average shares used in computing net loss per share:      
Basic and diluted   23,682,442       18,852,828  


Consolidated Balance Sheets
(Dollars in thousands, except for per share data)

  March 31,
  December 31,

Current assets:      
Cash and cash equivalents $ 49,658     $ 54,109  
Accounts receivable, net   2,243       2,337  
Inventory, net   5,732       4,938  
Prepaid expenses and other current assets   380       508  
Total current assets   58,013       61,892  
Property and equipment, net   709       539  
Operating lease rights of use   2,116       2,241  
Software license inventory   484       519  
Licensing rights   352       265  
Other assets   94       125  
Total assets $ 61,768     $ 65,581  
Current liabilities:      
Accounts payable $ 965     $ 427  
Accrued compensation   1,344       2,604  
Other accrued liabilities   602       537  
Operating lease liabilities, current portion   521       507  
Deferred product and service revenue, current portion   541       678  
Total current liabilities   3,973       4,753  
Operating lease liabilities, net of current portion   1,806       1,939  
Deferred product and service revenue, net of current portion   408       264  
2020 senior secured convertible notes payable, net   9,851       9,838  
Total liabilities   16,038       16,794  
Commitments and contingencies      
Stockholders’ equity:      
Preferred stock, $0.01 par value; 25,000,000 shares authorized; none issued and outstanding at March 31, 2022 and December 31, 2021          
Common stock, $0.01 par value; 200,000,000 shares authorized; 23,708,118 shares issued and outstanding at March 31, 2022; and 23,665,991 issued and outstanding at December 31, 2021   237       237  
Additional paid-in capital   183,384       182,482  
Accumulated deficit   (137,891 )     (133,932 )
Total stockholders’ equity   45,730       48,787  
Total liabilities and stockholders’ equity $ 61,768     $ 65,581  


Consolidated Statements of Cash Flows
(Dollars in thousands)

  For The Three Months Ended
March 31,
    2022       2021  
Cash flows from operating activities:      
Net loss $ (3,959 )   $ (2,538 )
Adjustments to reconcile net loss to net cash flows from operating activities:      
Allowance for doubtful accounts   (61 )     3  
Depreciation and amortization   86       15  
Share-based compensation   899       320  
Payment-in-kind interest         94  
Amortization of debt issuance costs and original issue discounts   13       35  
Amortization of lease rights of use, net of accretion in lease liabilities   133       133  
Increase (decrease) in cash resulting from changes in:      
Accounts receivable   155       (126 )
Inventory, net   (880 )     47  
Prepaid expenses and other current assets   128       (10 )
Other assets   30       3  
Accounts payable and accrued expenses   (692 )     (54 )
Lease liabilities   (128 )     (94 )
Deferred revenue   7       41  
Net cash flows from operating activities   (4,269 )     (2,131 )
Cash flows from investing activities:      
Purchases of property and equipment   (69 )     (40 )
Acquisition of licensing rights   (116 )      
Net cash flows from investing activities   (185 )     (40 )
Cash flows from financing activities:      
Proceeds from public offering of common stock, net of offering costs         46,785  
Proceeds from stock option and warrant exercises   3       145  
Net cash flows from financing activities   3       46,930  
Net change in cash and cash equivalents   (4,451 )     44,759  
Cash and cash equivalents, beginning of period   54,109       20,099  
Cash and cash equivalents, end of period $ 49,658     $ 64,858  
Cash paid for:      
Income taxes $     $  
Interest $ 100     $ 214  



Danilo D’Alessandro, Chief Financial Officer
(949) 900-6833

Caroline Corner, Investor Relations

Primary Logo

Source: ClearPoint Neuro, Inc.